Quick Dispatch:
Your tirzepatide vs dulaglutide Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide vs dulaglutide Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM ships.
Need Help?
Questions about tirzepatide vs dulaglutide Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide vs dulaglutide Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM in your area.
Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH
20.30
💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What
27.10
Tirzepatide vs. Dulaglutide: Cardiovascular Outcomes in Type 2 Diabetes
24.14
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide: A Randomized Clinical Trial: Annals of Internal Medicine: Vol 178, No 5
26.81
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes @NEJM Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to a composite of
28.31
Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT
22.69
Tirzepatide vs Dulaglutide in Diabetes and Cardiovascular Disease | Rami Fikri posted on the topic
23.46
